REPUBLIC OF KENYA

MINISTRY OF HEALTH

PHARMACY AND POISONS BOARD

PUBLIC ALERT

FALSIFIED POSTINOR-2 (LEVONORGESTREL 0.75MG) TABLETS BATCH NUMBER T34197R

The Pharmacy and Poisons Board ("the Board") is the National Medicines Regulatory Authority of Kenya, established under Section 3 of the Pharmacy and Poisons Act, Cap 244 of the Laws of Kenya. The Board is mandated to protect and promote public health by regulating the pharmacy profession and ensuring access to quality, safe, and effective health products and technologies ("HPTs")

In furtherance of this mandate, the Board undertakes post-marketing surveillance activities to monitor HPTs circulating in the market and to take appropriate regulatory actions in safeguarding public health.

The Board detected a falsified **POSTINOR-2** ***(Levonorgestrel 0.75mg tablets)*** **Batch No. T34197R,** misleadingly claiming to be manufactured by Gedeon Richter. This falsified product was found in circulation in the Kenyan market.

A comparison between the falsified and the genuine Postinor-2 supplied by Gedeon Richter Plc. revealed several noticeable differences, including:

1. The batch printing method differs from the one used on authentic Gedeon Richter products.
2. The Patient Information Leaflet contains several printing and typographical errors.
3. The carton sealing method is different. Genuine Gedeon Richter packs are sealed using a hot melt closure, whereas the falsified pack is not.
4. The orange colour used on the brand name and other areas of the pack is significantly more intense than on the genuine product.
5. The font of the logo revealed after scratching the authentication panel is different from that of the genuine pack.

These observations strongly indicate that the product is falsified and is not manufactured or released by Gedeon Richter.

Risks

This batch of falsified Postinor-2 may contain incorrect amounts of the active ingredient, no active ingredient at all, harmful contaminants, or undeclared substances, and therefore may not provide the intended therapeutic effect.

PUBLIC ADVISORY

In light of the above, the Board advises as follows:

1. Healthcare professionals are advised to remain vigilant, verify the authenticity of stocks before dispensing and to quarantine any suspected falsified products.
2. Procurement agencies, hospitals, distributors, pharmacists, pharmaceutical technologists, and members of the public are urged **to remain vigilant and report immediately any encounter with the falsified Postinor-2 batch T34197R.**
3. All stakeholders within the supply chain to procure HPTs exclusively from PPB licensed manufacturers, importers, distributors, and retailers. Procuring from unlicensed sources endangers patients and constitutes a violation of the Pharmacy and Poisons Act, Cap 244 of the Laws of Kenya.

The Board, in collaboration with the relevant Government investigative and enforcement agencies, has made significant progress in investigations, including the arrest of two (2) individuals found in possession of the falsified product. Further investigations are ongoing to establish the source of the product, the point of entry into the country, and the extent of distribution within the supply chain. The Board will continue to take firm regulatory and legal action against all persons found to be involved in the manufacture, importation, distribution or supply of falsified health products and technologies.

HOW TO REPORT

Any suspected falsified or substandard medicine should be reported through the following official channels:

- Online portal: https://pv.pharmacyboardkenya.org/users/mpublic
- USSD Code: *271#
- Mobile App: mPvERS (Android & iOS)
- Email: pv@ppb.go.ke | pms@ppb.go.ke
- Telephone: 0795743049

The Pharmacy and Poisons Board remains committed to protecting and safeguarding public health. Your cooperation is essential in ensuring the quality, safety, and efficacy of Health Products and Technologies in Kenya

Dr. Ahmed. I. Mohamed
CHIEF EXECUTIVE OFFICER
7th August 2026